Genocea Biosciences Inc (NASDAQ:GNCA) shares gapped up prior to trading on Thursday . The stock had previously closed at $4.43, but opened at $4.03. Genocea Biosciences shares last traded at $3.99, with a volume of 8,273 shares traded.
GNCA has been the subject of several recent analyst reports. ValuEngine upgraded shares of Genocea Biosciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 1st. Needham & Company LLC reiterated a “buy” rating on shares of Genocea Biosciences in a report on Friday, March 1st. Finally, Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st.
The company has a debt-to-equity ratio of 1.45, a quick ratio of 2.51 and a current ratio of 2.51. The company has a fifty day moving average of $3.86.
In related news, major shareholder Peter W. Sonsini purchased 2,857,142 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average cost of $3.50 per share, for a total transaction of $9,999,997.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.33% of the company’s stock.
A hedge fund recently raised its stake in Genocea Biosciences stock. Fosun International Ltd boosted its holdings in shares of Genocea Biosciences Inc (NASDAQ:GNCA) by 41.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 571,028 shares of the biotechnology company’s stock after acquiring an additional 167,350 shares during the quarter. Fosun International Ltd owned approximately 0.51% of Genocea Biosciences worth $345,000 at the end of the most recent reporting period.
About Genocea Biosciences (NASDAQ:GNCA)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Recommended Story: Hold Rating
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.